2Q EARNINGS: Aegerion beats consensus, raises Juxtapid guidance
This article was originally published in Scrip
Executive Summary
Aegerion Pharmaceuticals beat Wall Street consensus for its first full quarter of Juxtapid (lomitapide) sales and raised its guidance for full-year 2013 revenue from the homozygous familial hypercholesterolemia (HoFH) drug.